NEW YORK (GenomeWeb News) - PrognosDx Health has signed an exclusive, worldwide license for the patent rights associated with epigenetics technology developed at the University of California, Los Angeles, the company said today.

The technology, developed by Siavash Kurdistani and David Seligson at UCLA, is based on the predictive power of global histone modification patterns and "has broad potential uses in the development of cancer prognostic assays including response predictions to therapeutics as well as research tools and reagents," PrognosDx said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.